Still, the ability to redeploy oncology-grade CAR-T platforms for immune-mediated disorders marks one of the most exciting evolutions in cell therapy today
Komabayashi T, Yakata A, Izawa T, Suda K, Noguchi M, Tsuboi M
The second receptor target is GIP (glucose-dependent insulinotropic polypeptide), which works synergistically with GLP-1 to enhance insulin sensitivity and further regulate appetite
The detoxification enzyme systems
Un registro preciso tambin facilita la comunicacin con el equipo de atencin mdica, permitiendo ajustes informados del tratamiento basados en la respuesta individual y la tolerabilidad del medicamento
Understanding these potential mechanisms helps clinicians counsel patients appropriately and distinguish between expected treatment effects and concerning adverse reactions